Peer-Reviewed Publications - Shari Pilon-Thomas, Ph.D.


  1. Bazargan S., Bunch, B., Ojwang A.M.E., Blauvelt J., Landin A., Ali J., Abrahams D., Cox CA, Hall AM, Beatty MS, Poch M., Rejniak KA, & Pilon-Thomas S. Targeting Myeloid-Derived Suppressor Cells (MDSCs) with Gemcitabine to Enhance Efficacy of Adoptive Cell Therapy (ACT) in Bladder Cancer. Frontiers in Immunology. 2023; doi: 10.3389/fimmu.2023.1275375.  

  2. Hall MS, Teer JK, Yu X, Branthoover H, Snedal S, Rodriguez-Valentin M, Nagle L, Scott E, Schachner B, Innamarato P, Hall AM, Blauvelt J, Rich CJ, Richards AD, Ceccarelli J, Langer TJ, Yoder SJ, Beatty MS, Cox CA, Messina JL, Abate-Daga D, Mule JJ, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Neoantigen-specific CD4(+) tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. J Immunother Cancer. 2023;11(10). doi: 10.1136/jitc-2023-007288. PubMed PMID: 37802604.

  3. Dukes CW, Rossetti RAM, Hensel JA, Snedal S, Cubitt CL, Schell MJ, Abrahamsen M, Isaacs-Soriano K, Kennedy K, Mangual LN, Whiting J, Martinez-Brockhus V, Islam JY, Rathwell J, Beatty M, Hall AM, Abate-Daga D, Giuliano AR, & Pilon-Thomas S. SARS-CoV-2 Antibody Response Duration and Neutralization Following Natural Infection [published online ahead of print]. J Clin Virol Plus. 2023;3(3). doi:10.1016/j.jcvp.2023.100158

  4. Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ, Colon Colon M, Schell MJ, Teer JK, Khushalani NI, Weber JS, Mule JJ, Sondak VK, Pilon-Thomas S, Sarnaik AA. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Clin Cancer Res. 2022. Epub 20221010. doi: 10.1158/1078-0432.CCR-22-2103. PubMed PMID: 36215121

  5. Giuliano AR, Kuter BJ, Pilon-Thomas S, Whiting J, Mo Q, Leav B, Sirak B, Cubitt CL, Dukes C, Isaacs-Soriano K, Kennedy K, Ball S, Dong N, Jain A, Hwu P, & Lancet JE. Safety and Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients [published online ahead of print, 2023 Jun 28]. Cancer Commun (Lond). 2023;10.1002/cac2.12453. doi:10.1002/cac2.12453

  6. Gallen C, Dukes CW, Aldrich A, Macaisa L, Mo Q, Cubitt CL, Pilon-Thomas S, Giuliano AR, Czerniecki BJ, & Costa RLB. Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study. Vaccines. 2022;10(11):1931. doi:10.3390/vaccines10111931

  7. Giuliano AR, Lancet JE, Pilon-Thomas S, Dong N, Jain AG, Tan E, Ball S, Tworoger SS, Siegel EM, Whiting J, Mo Q, Cubitt CL, Dukes CW, Hensel JA, Keenan RJ, & Hwu P. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida. JAMA Oncol. 2022;8(5):748-754. doi:10.1001/jamaoncol.2022.0001

  8. Giuliano AR, Pilon-Thomas S, Schell MJ, Abrahamsen M, Islam JY, Isaacs-Soriano K, Kennedy K, Dukes CW, Whiting J, Rathwell J, Hensel JA, Mangual LN, Schonbrunn E, Bikowitz M, Grassie D, & Yang Y. SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020-March 2021. Emerg Infect Dis. 2022;28(3):556-563. doi:10.3201/eid2803.211495

  9. Aydin AM, Hall M, Bunch BL, Branthoover H, Sannasardo Z, Mackay A, Beatty M, Sarnaik AA, Mullinax JE, Spiess PE, Pilon-Thomas S. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. Int Immunopharmacol. 2021 Feb 23;94:107481. doi: 10.1016/j.intimp.2021. PMID: 10748133636562

  10. Innamarato P, Pilon-Thomas S. Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy. Cell Immunol. 2021 Mar;361:104277. doi: 10.1016/j.cellimm.2020.104277. Epub 2020 Dec 26. PMID: 33476931

  11. Mullinax JE, Hall M, Beatty M, Weber AM, Sannasardo Z, Svrdlin T, Richards A, Gonzalez RJ, Cox CA, Kelley L, Mulé JJ, Sarnaik AA, Pilon-Thomas S. Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function. J Immunother. 2021 Jan 11. doi: 10.1097/CJI.0000000000000355. Online ahead of print. PMID: 33443972

  12. Wu H, Estrella V, Beatty M, Abrahams D, El-Kenawi A, Russell S, Ibrahim-Hashim A, Longo DL, Reshetnyak YK, Moshnikova A, Andreev OA, Luddy K, Damaghi M, Kodumudi K, Pillai SR, Enriquez-Navas P, Pilon-Thomas S, Swietach P, Gillies RJ. T-cells produce acidic niches in lymph nodes to suppress their own effector functions. Nat Commun. 2020 Aug 17;11(1):4113. doi: 10.1038/s41467-020-17756-7. PMID: 32807791

  13. Mohamed E, Sierra RA, Trillo-Tinoco J, Cao Y, Innamarato P, Payne KK, de Mingo Pulido A, Mandula J, Zhang S, Thevenot P, Biswas S, Abdalla SK, Costich TL, Hänggi K, Anadon CM, Flores ER, Haura EB, Mehrotra S, Pilon-Thomas S, Ruffell B, Munn DH, Cubillos-Ruiz JR, Conejo-Garcia JR, Rodriguez PC. The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity. 2020 Apr 14;52(4):668-682.e7. doi: 10.1016/j.immuni.2020.03.004. PMID: 32294407

  14. Innamarato P, Asby S, Morse J, Mackay A, Hall M, Kidd S, Nagle L, Sarnaik AA, Pilon-Thomas S. Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells. J Immunol. 2020 Nov 15;205(10):2893-2904. doi: 10.4049/jimmunol.2000759. Epub 2020 Oct 5. PMID: 33020146

  15. Innamarato P, Kodumudi K, Asby S, Schachner B, Hall M, Mackay A, Wiener D, Beatty M, Nagle L, Creelan BC, Sarnaik AA, Pilon-Thomas S. Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy. Mol Ther. 2020 Oct 7;28(10):2252-2270. doi: 10.1016/j.ymthe.2020.06.025. Epub 2020 Jun 24. PMID: 32615068

  16. Bunch BL, Morse J, Asby S, Blauvelt J, Aydin AM, Innamarato P, Hajiran A, Beatty M, Poch M, Pilon-Thomas S. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. J Immunother Cancer. 2020 Dec;8(2):e001673. doi: 10.1136/jitc-2020-001673. PMID: 33303579

  17. Hopewell EL, Cox C, Pilon-Thomas S, Kelley LL. Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process. Cytotherapy. 2019 Mar;21(3):307-314. doi: 10.1016/j.jcyt.2018.11.004. Epub 2018 Dec 1. PMID: 30509772

  18. Falahat R, Perez-Villarroel P, Mailloux AW, Zhu G, Pilon-Thomas S, Barber GN, Mulé JJ. STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity. Cancer Immunol Res. 2019 Nov;7(11):1837-1848. doi: 10.1158/2326-6066.CIR-19-0229. Epub 2019 Aug 28. PMID: 31462408

  19. El-Kenawi A, Gatenbee C, Robertson-Tessi M, Bravo R, Dhillon J, Balagurunathan Y, Berglund A, Vishvakarma N, Ibrahim-Hashim A, Choi J, Luddy K, Gatenby R, Pilon-Thomas S, Anderson A, Ruffell B, Gillies R. Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer. Br J Cancer. 2019 Oct;121(7):556-566. doi: 10.1038/s41416-019-0542-2. Epub 2019 Aug 16. PMID: 31417189

  20. Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards AD, Moberg VE, Pilon-Thomas S, Schell MJ, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI. BRAF targeting sensitizes resistant melanoma to cytotoxic T cells. Clin Cancer Res. 2019 Feb 14. pii: clincanres.2725.2018. doi: 10.1158/1078-0432.CCR-18-2725. PMID: 30765391

  21. Hopewell EL, Cox C, Pilon-Thomas S, Kelley LL. Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process. Cytotherapy. 2018 Nov 30. pii: S1465-3249(18)30674-1. PMID: 30509772

  22. Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer.  Oncoimmunology. 2018 Jul 23;7(9):e1476816. PMCID: PMC6140546

  23. Liu H, Weber A, Morse J, Kodumudi K, Scott E, Mullinax J, Sarnaik AA, Pilon-Thomas S. T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model. PLoS One. 2018 Apr 25;13(4):e0196033. PMCID: PMC5918896

  24. Mullinax, JE, Hall, M., Prabhakaran, S., Weber, J, Khushalani, N., Eroglu, Z, Brohl, A., Markowitz,J., Royster, E., Richards, A., Stark, V.,  Zager, JS.,  Kelley, L., Cox,C., Sondak, VK., Mule', JJ., Pilon-Thomas, S.*, and  Sarnaik, AA.  Combination Ipilimumab and Adoptive Cell Therapy with Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma.  Frontiers in Oncology. 2018. Front Oncol. 2018 Mar 2;8:44. PMCID: PMC5840208. *corresponding author and shared senior authorship

  25. Hall, M., Liu, H., Malafa, M., Centeno, B., Pimiento, J., Hodel, P., Pilon-Thomas, S.*, Sarnaik, AA. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer. 4:61.2016. PMCID: PMC5067894. *shared senior authorship

  26. Liu H, Innamarato PP, Kodumudi K, Weber A, Nemoto S, Robinson JL, Crago G, McCardle T, Royster E, Sarnaik AA, Pilon-Thomas S. Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget. 2016. PMCID: PMC5122358

  27. Kodumudi KN, Siegel J, Weber AM, Scott E, Sarnaik AA, Pilon-Thomas S. Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy. PLoS One.11(4):e0153053. 2016. PMCID:PMC4822778

  28. Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Damaghi M, Wojtkowiak JW, Mulé JJ, Ibrahim-Hashim A, Gillies RJ. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 76(6):1381-90, 2016. PMCID: PMC4829106

  29. Chacon, J., Sarnaik, A.A., Chen, J., Creasy, C., Kale, C., Robinson, J., Weber, J., Hwu, P., Pilon-Thomas, S.*, and Radvanyi, L. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy. Clinical Cancer Research, 21(3):611-21, 2015. PMCID: PMC4315752 *shared senior authorship

  30. Chacon, J.A., Pilon-Thomas, S., Sarnaik, A.A., Radvanyi, L.G. Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology. 2(9):e25581, 2013. PMID: 24319633; PMCID: PMC3850170.

  31. Toomey, P., Kodumudi, K., Weber, A., Kuhn, L., Moore, E., Sarnaik, A.A., Pilon-Thomas, S. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS One. 8(7):e68561, 2013. PMCID: PMC3714270

  32. Ghansah, T., Vohra, N., Kinney, K., Weber, A., Kodumudi, K., Springett, G., Sarnaik, A.A., Pilon-Thomas, S. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunol Immunother., 62(6):1083-91, 2013. PMCID: PMC3666559

  33. Chacon, J.A., Wu, R.C., Sukhumalchandra, P., Molldrem, J.J., Sarnaik A, Pilon-Thomas, S., Weber, J., Hwu, P., Radvanyi, L. Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy. PLoS One, 8(4):e60031, 2013. Epub 2013 Apr 1. PMCID: PMC3613355

  34. Kodumudi, K., Weber, A., Sarnaik, A.A., Pilon-Thomas, S. Blockade of myeloid derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. Journal of Immunology 189(11): 5147-54, 2012. PMCID: PMC3505990

  35. Pilon-Thomas, S., Kuhn, L., Ellwanger, S., Janssen, W., Royster, E., Marzban, S., Kudchadkar, R., Zager, J., Gibney, G., Sondak, V.K., Weber, J., Mulé, J.J., Sarnaik, A.A. Brief Communication: Efficacy of Adoptive Cell Transfer of Tumor Infiltrating Lymphocytes after Lymphopenia Induction for Metastatic Melanoma. Journal of Immunotherapy 35:615-20, 2012. PMCID: PMC4467830

  36. Pilon-Thomas, S., Nelson, N., Vohra, N., Jerald, M., Pendleton, L., Szekeres,K, and Ghansah, T. Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function.  PLoS One, 6:e27729, 2011.  PMCID: PMC3222660

  37. Pilon-Thomas, S.A., Mackay, A., Vohra, N., and Mulé, J.J. Blockade of Programmed Death Ligand-1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J. Immunol. 184:3442-3449, 2010.  PMCID: PMC2913584